Antimalarial Compound Improves Forensics of Bloodstains
By LabMedica International staff writers Posted on 12 Jun 2017 |

Image: Determining which stain on these paper filters (top row) is from blood (C) rather than coffee (A) or tea (B) is easier with the new, more selective artemisinin-luminol chemiluminescence test for forensic bloodstain detection (bottom row) (Photo courtesy of ACS).
Forensic investigators often use a luminol chemiluminescence test to detect latent bloodstains at crime scenes. Now, researchers have found that combining luminol with the antimalarial drug artemisinin, a natural peroxide, reduces the risk of false positives compared to the traditional method that mainly uses hydrogen peroxide or sodium perborate as coreactants. They also obtained test results using a smartphone, which could provide highly accurate on-scene analyses.
Luminol is often combined with hydrogen peroxide to react with the heme groups in blood, producing the blue chemiluminescent glow. This allows crime scene technicians to detect blood on surfaces. While this test has proven beneficial in numerous criminal investigations, false positives due to interferences from biomolecules and metal ions, as well as from the breakdown products of hydrogen peroxide, can occur.
In an effort to minimize erroneous identifications, Prof. Guobao Xu of ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences (Changchun, Jilin, China) and colleagues investigated the use of artemisinin with luminol as artemisinin is more structurally sound and more resistant to interferences than hydrogen peroxide.
The researchers showed that the luminol-artemisinin combination is more selective than luminol-hydrogen peroxide, resulting in fewer false positives when challenged with components of bleaches and disinfectants, which criminals often use to cover up a misdeed. The method could distinguish blood from coffee, tea, and brown sugar stains.
The study, by Gao W et al, was published May 11, 2017, in the journal Analytical Chemistry.
Related Links:
ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences
Luminol is often combined with hydrogen peroxide to react with the heme groups in blood, producing the blue chemiluminescent glow. This allows crime scene technicians to detect blood on surfaces. While this test has proven beneficial in numerous criminal investigations, false positives due to interferences from biomolecules and metal ions, as well as from the breakdown products of hydrogen peroxide, can occur.
In an effort to minimize erroneous identifications, Prof. Guobao Xu of ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences (Changchun, Jilin, China) and colleagues investigated the use of artemisinin with luminol as artemisinin is more structurally sound and more resistant to interferences than hydrogen peroxide.
The researchers showed that the luminol-artemisinin combination is more selective than luminol-hydrogen peroxide, resulting in fewer false positives when challenged with components of bleaches and disinfectants, which criminals often use to cover up a misdeed. The method could distinguish blood from coffee, tea, and brown sugar stains.
The study, by Gao W et al, was published May 11, 2017, in the journal Analytical Chemistry.
Related Links:
ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more